A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Public ClinicalTrials.gov record NCT05277571. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2A, Randomized, Placebo-Controlled, Single-Ascending Dose (Part A, Participant- and Investigator-Blind) and Repeat-Dose (Part B, Participant-, Investigator-, and Sponsor-Blind) Study to Investigate the Safety, Pharmacokinetics, and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Study identification
- NCT ID
- NCT05277571
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- UCB Biopharma SRL
- Industry
- Enrollment
- 109 participants
Conditions and interventions
Conditions
Interventions
- UCB1381 Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2022
- Primary completion
- Jul 16, 2025
- Completion
- Sep 18, 2025
- Last update posted
- Jun 24, 2026
2022 – 2025
United States locations
- U.S. sites
- 16
- U.S. states
- 8
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Up0110 125 | Beverly Hills | California | 90212 | — |
| Up0110 101 | Glendale | California | 91206 | — |
| Up0110 116 | Los Angeles | California | 90045 | — |
| Up0110 121 | Northridge | California | 91324 | — |
| Up0110 126 | Tustin | California | 92780 | — |
| Up0110 127 | Valencia | California | 91355 | — |
| Up0110 108 | Clearwater | Florida | 33765 | — |
| Up0110 109 | Miami Lakes | Florida | 33014 | — |
| Up0110 106 | Ocala | Florida | 34471 | — |
| Up0110 102 | St. Petersburg | Florida | 33705 | — |
| Up0110 111 | College Park | Georgia | 30349 | — |
| Up0110 114 | Minneapolis | Minnesota | 55455 | — |
| Up0110 107 | New York | New York | 10029 | — |
| Up0110 124 | Winston-Salem | North Carolina | 27103 | — |
| Up0110 104 | Oklahoma City | Oklahoma | 73170 | — |
| Up0110 119 | Philadelphia | Pennsylvania | 19103 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05277571, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 24, 2026 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05277571 live on ClinicalTrials.gov.